Good News: Sigh of relief as Nigerian priests finally develop COVID-19 drug(Read full details)

A group of Nigerian Catholic priests have developed a supposed cure for the deadly COVID-19 pandemic, a drug called Pax CVD Plus.
The disclosure was made in a statement released and signed by Father Anselm Adodo OSB on Wednesday, April 29, on the official page of the Pax Herbal Clinic and Research Laboratories, Outcome News reports.
Father Anselm said that plant-based drugs are seemingly the best approach for coronavirus because these drugs are easily produced, stored and distributed and can be handled by medical and non-medical personnel as they pose a low contamination risk.
He said the constituents of the drug are antiviral and immunomodulatory agents which help to stimulate antibodies.
The cleric said: “The Pax CVD PLUS contains herbs and active phytoconstituents with documented scientific evidence based on clinical reports of their efficacy and safety.”
According to Father Anselm, the research is a joint effort of experts from University of Lagos and University of Benin, a tertiary health institution—Irrua Specialist Teaching Hospital, Edo state and experts sent by Prof Tunde Salako and Prof Catherine Adeyeye
Professor Salako is the head of the National Institute of Pharmaceutical Research and Development, while Professor Adeyeye is the director-general of the National Agency for Food and Drug Administration and Control.
The disclosure was made on Monday, April 27, by a Facebook user named Seyi Fasugba, who said the deceased was always willing and ready to offer assistance to many Nigerians in London.
The deceased was survived by his four children. Fasugba posted on Facebook: "Lost A Dependable Friend To Coronavirus In UK.
"Yemi Ogunsina, a childhood friend lived as an inspiration to many Nigerians in London, Birmingham. Always willing and ready to offer assistance particularly on immigration issues."
Read full details
Source:https://www.royalng.com/good-news-sigh-of-relief-as-nigerian-priests-finally-develop-covid-19-drugread-full-details-2/